{"groups":[{"description":"Bintrafusp alfa (M7824): 1200mg, over 60 minutes IV infusion The treatment will start within 1-5 days from enrollment. The treatment will be administered at day 1 of 14-day intervals .\n\nTreatment will be administered until unacceptable toxicity, loss of clinical benefit, disease progression or completion of 2 years of therapy. If the patient has benefit after 2 years, the trial chair and the sponsor must be consulted to evaluate how to continue with the treatment.","id":"FG000","title":"Experimental: Bintrafusp Alfa (M7824)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}